Investing.com - Lucid Capital Markets initiated coverage on Microbot Medical (NASDAQ:MBOT) with a buy rating and a price target of $4.00, according to a report released Tuesday. The stock currently trades at $2.01, representing a potential upside of nearly 100% to the analyst’s target. According to InvestingPro data, the company holds more cash than debt on its balance sheet and posted a significant 17.5% return over the last week. The stock appears overvalued based on InvestingPro’s Fair Value analysis, though analyst targets range from $5 to $12.
The research firm highlighted the limited adoption of robotic systems in endovascular procedures. The U.S. endovascular intervention market comprises approximately 5 million to 6 million procedures annually, including roughly 3 million coronary, 2 million to 2.5 million peripheral, and the remainder neurovascular procedures.
These procedures are performed by a concentrated base of around 15,000 physicians across approximately 8,000 facilities, representing at least $40 billion in annual spending. Less than 1% of these procedures are currently performed robotically.
Lucid Capital Markets noted that existing medical robotic systems are characterized by large capital requirements, proprietary tools, slow setup times, and difficulty fitting into catheterization laboratories. The firm described Microbot’s Liberty system as a novel approach in a largely untapped category.
The analyst views the company’s entry into the peripheral vascular market as an early-stage opportunity. With a market cap of $135 million and a strong current ratio of 22.59, the company maintains solid liquidity despite not yet being profitable. InvestingPro offers 6 additional exclusive tips and comprehensive financial metrics for investors evaluating this early-stage opportunity.
In other recent news, Microbot Medical Inc. reported that its second quarter revenue has surpassed the first quarter’s figures, following the Full Market Release of its LIBERTY Endovascular Robotic System. This financial update highlights the company’s growth in revenue as it advances its product availability. Additionally, Microbot Medical has secured its first customer in North Carolina, marking an expansion into the Southeast and Mid-Atlantic regions of the U.S.
The company also received marketing clearance from Israel’s Ministry of Health for its LIBERTY System, making Israel the first jurisdiction outside the U.S. to approve the device. This approval allows Microbot Medical to market and commercialize the system in Israel and supports further regulatory submissions in other regions. In leadership news, Microbot Medical appointed Alon Tamir as Vice President of Sales for Europe, the Middle East, and Asia to spearhead sales strategies and partnerships in these regions.
However, a recent report by White Diamond Research expressed skepticism about the commercial viability of the LIBERTY System, setting a $1 price target on the stock and disclosing a short position. Despite this, Microbot Medical continues to focus on expanding its market presence and product reach. These developments reflect the company’s ongoing efforts to enhance its market position and operational capabilities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates MBOT alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if MBOT is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?